In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease

Clinical Cancer Research

Volumn 6, Issue 2, 2000, Pages 585-596

  Pilarski, Linda M ^a   Giannakopoulos, Nadia V ^a   Szczepek, Agnieszka J ^a   Masellis, Anna M ^a   Mant, Michael J ^a   Belch, Andrew R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD34 ANTIGEN; DNA; IMMUNOGLOBULIN HEAVY CHAIN;

ANEUPLOIDY; ARTICLE; B LYMPHOCYTE; CARCINOGENESIS; DISEASE COURSE; DNA DETERMINATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

B-LYMPHOCYTES; BONE MARROW CELLS; DIPLOIDY; GENE REARRANGEMENT; GENES, IMMUNOGLOBULIN; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, B-CELL, CHRONIC; MULTIPLE MYELOMA; PROGNOSIS; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC;

EID: 0033977906     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Bergsagel, D. E. Treatment of plasma cell myeloma. Ann. Rev. Med., 30: 431-433, 1979.
2. Palmer, M., Belch, A., Hanson, J., and Brox, L. Reassessment of the relationship between M-protein decrement and survival in multiple myeloma. Br. J. Cancer, 59: 110-112, 1989.
3. Attal, M., Harosseau, J-L., Stoppa, A-M., Sotto, J-J., Fuzibet, J-G., Rossi, J-F., Cassasus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C., and Batialle, R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med., 335: 91-97, 1996.
4. Pilarski, L. M., Mant, M. J., and Belch, A. R. Circulating, monoclonal, multi-drug resistant B cells may comprise the malignant stem cells population in multiple myeloma. In: F. Dammaco and B. Barlogie (eds.), Challenges in Modern Medicine, Vol. 4, pp. 31-39, 1994.
5. Jensen, G. S., Mant, M. J., Belch, A. R., Berensen, J. R., Ruether, B. A., and Pilarski, L. M. Selective expression of CD45 isoforms defines CALLA+ monoclonal B lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood, 78: 711-719, 1991.
6. Pilarski, L. M., and Jensen, G. S. Monoclonal circulating B cells in multiple myeloma: a continuously differentiating possibly invasive population as defined by expression of CD45 isoforms and adhesion molecules. Hematol. Oncol. Clin. N. Am., 6: 297-322, 1992.
7. Szczepek, A. J., Bergsagel, P. L., Axelsson, L., Brown, C. B., Belch, A. R., and Pilarski, L. M. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ rearrangements. Blood, 89: 1824-1833, 1997.
8. Pilarski, L. M., Szczepek, A. J., and Belch, A. R. Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma. Blood, 90: 3751-3759, 1997.
9. Masellis-Smith, A., Belch, A. R., Mant, M. J., Turley, E. A., and Pilarski, L. M. Hyaluronan-dependent motility of B cells and leukemic plasma cells but not of bone marrow plasma cells in multiple myeloma: alternate usage of RHAMM and CD44. Blood, 87: 1891-1899, 1996.
10. Szczepek, A. J., Seeberger, K., Wizniak, J., Mant, M. J., Belch, A. R., and Pilarski, L. M. A high frequency of circulating B cells share clonotypic IgH VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in situ RT-PCR. Blood, 92: 2844-2855, 1998.
11. Bergsagel, P. L., Masellis, S., Szczepek, A., Mant, M. J., Belch, A. R., and Pilarski, L. M. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic immunoglobulin light chain. Blood, 85: 436-447, 1995.
12. Kubagawa, H., Vogler, L. B., Capra, J. D., Conrad, M. E., Lawton, A. R., and Cooper, M. D. Studies on the clonal origin of multiple myeloma. J. Exp. Med., 150: 792-807, 1979.
13. Szczepek, A. J., Belch, A. R., and Pilarski, L. M. Evidence that myeloma may originate from an antigen-driven clone that persists after malignant transformation: pre-switch B cells in the circulation of myeloma patients exhibit mutational diversity in the variable region of clonal IgM and IgD transcripts. Blood, 92: 257a-257a, 1998.
14. Bakkus, M. H. C., Van Riet, I., Van Camp, B., and Thielemann, K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br. J. Haematol., 87: 68-74, 1994.
15. Billadeau, D., Ahmann, G., Greipp, P., and Van Ness, B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J. Exp. Med., 178: 1023-1031, 1993.
16. Corradini, P., Boccadoro, M., Voena, C., and Pilieri, A. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to c-mu sequence in immunoglobulin (IgG) and IgA secreting multiple myelomas. J. Exp. Med., 178; 1091-1096, 1993.
17. Mellstedt, H., Hammarstrom, S., and Holm, G. Monoclonal lymphocytes in human plasma cell myeloma. Clin. Exp. Immunol., 17: 371-384, 1974.
18. King, M. A., and Nelsonm, D. S. Tumor cell heterogeneity in multiple myeloma: antigenic, morphologic, and functional studies of cells from blood and bone marrow. Blood, 73: 1925-1935, 1989.
19. Bloem, A. C., Chand, M. A., van Camp, B., Bast, E. J., and Ballieux, R. E. Phenotypical and functional characterization of the idiotype-positive blood B cells in multiple myeloma. Scand. J. Immunol., 28: 791-799, 1988.
20. Mellstedt, H., Holm, G., Pettersson, D., and Peest, D. Idiotype-bearing lymphoid cells in plasma cell neoplasia. Clin. Haematol., 11: 65-86, 1982.
21. Osterborg, A., Steinitz, M., Lewin, N., Bergenbrant, S., Holm, G., Lefvert, A. K., and Mellstedt, H. Establishment of idiotype bearing B-lymphocyte clones from a patient with monoclonal gammopathy. Blood, 78: 2642-2649, 1991.
22. Pettersson, D., Mellstedt, H., and Holm, G. Monoclonal B lymphocytes in multiple myeloma. Scand. J. Immunol., 12: 375-382, 1980.
23. Billadeau, D., Quam, L., Thomas, W., Kay, N. E., Greipp, P., Kyle, R., Oken, M. M., and Van Ness, B. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood, 80: 1818-1824, 1992.
24. Billadeau, D., Van Ness, B., Kimlinger, T., Kyle, R. A., Therneau, T. M., Greipp, P. R., and Witzig, T. E. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood, 88: 289-296, 1996.
25. Brown, R., Luo, X. F., Gibson, J., Morley, A., Sykes, P., Brisco, M., and Joshua, D. Idiotypic oligonucleotide probes to detect myeloma cells by mRNA in situ hybridization. Br. J. Haematol., 90: 113-118, 1998.
26. Chen, B. J., and Epstein, J. Circulating clonal lymphocytes in myeloma constitute a minor population of B cells. Blood, 87: 1972-1976, 1996.
27. Pilarski, L. M., Hipperson, G., Seeberger, K., Pruski, E., Coupland, R. W., and Belch, A. R. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood, in press, 1999.
28. McSweeney, P. A., Wells, D. A., Shults, K. E., Nash, R. A., Bensinger, W. I., Buckner, C. D., and Loken, M. R. Tumor-specific aneuploidy not detected in CD19+ B lymphoid cells from myeloma patients in a multidimensional flow cytometry analysis. Blood, 88: 622-632, 1996.
29. Latreille, J., Barlogie, B. A., Dosik, G. A., Johnson, D. A., Drewinko, B., and Alexanian, R. Cellular DNA content as a marker of human multiple myeloma. Blood, 55: 81-90; 403-408, 1980.
30. Montecucco, C., Riccardi, A., Merlini, G., Mazzini, G., Giordano, P., Danova, M., and Ascari, E. Plasma cell DNA content in multiple myeloma and related paraproteinemic disorders. Relationship with clinical and cytokinetic features. Br. J. Cancer Clin. Oncol., 20: 81-90, 1984.
31. Morgan, R. J., Jr., Gonchoroff, N. J., Katzmann, J. A., Witzig, T. E., Kyle, R. A., and Greipp, P. R. Detection of hypodiploidy using multiparameter flow cytometric analysis: a prognostic indicator in multiple myeloma. Am. J. Hematol., 30: 195-200, 1989.
32. Tienhaara, A., and Pelliniemi, T. T. Flow cytometric DNA analysis and clinical correlations in multiple myeloma. Am. J. Clin. Pathol., 97: 322-330, 1992.
33. Tsuchiya, H., Welhamepstein, J., Selvanayagam, P., Dedman, J. R., Gallick, G., Alexanian, R., and Barlogie, B. Correlated flow cytometric analysis of Ha-ras p21 and nuclear DNA in multiple myeloma. Blood, 72: 796-800, 1988.
34. Tafuri, A., Meyers, J., Lee, B. J., and Andreeff, M. DNA and RNA flow cytometric study in multiple myeloma. Cancer (Phila.), 67: 449-454: 1991.
35. Shimazaki, C., Gotoh, H., Ashihara, E., Oku, N., Inaba, T., Murakami, S., Itoh, K., Ura, Y., Nakagawa, M., and Fujita, N. Immunophenotype, and DNA content of myeloma cells in primary plasma cell leukemia. Am. J. Hematol., 39: 159-162, 1992.
36. Zandecki, M., Bernardi, F., Lai, J. L., Facon, T., Izydorczyk, V., Bauters, F., and Cosson, A. Image analysis in multiple myeloma at diagnosis. Correlation with cytogenetic study. Cancer Genet. Cytogenet., 74: 115-119, 1994.
37. Garcia-Sanz, R., Orfao, A., Gonzalez, M., Moro, M. J., Hernandez, J. M., Ortega, F., Borrego, D., Carnero, M., Casanova, F., Jimenez, R., Portero, J. A., and San Miguel, J. F. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Br. J. Haematol., 90: 106-112, 1995.
38. Lai, J. L., Zandecki, M., Mary, J. Y., Bernardi, F., Izydorczyk, V., Flactif, M., Morel, P., Jouet, J. P., Bauters, F., and Facon, T. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood, 85: 2490-2497, 1995.
39. Pilarski, L. M., Masellis Smith, A., Belch, A. R., Yang, B., Savani, R. C., and Turley, E. A. RHAMM, a receptor for hyaluronan-mediated motility, on normal lymphocytes, thymocytes and in B cell malignancy: a mediator in B cell malignancy? Leuk. Lymphoma, 14: 363-374, 1994.
40. Pilarski, L. M., and Belch, A. R. Circulating monoclonal B cells expressing p-glycoprotein may be a reservoir of multidrug resistant disease in multiple myeloma. Blood, 83: 724-736, 1994.
41. Coleman, A. W., Maguire, M. J., and Coleman, J. R. Mithramycin and 4′-6′-diamidino-2-phenylindole (DAPI)-DNA staining for fluorescence microspectrophotometric measurement of DNA in nuclei, plastids, and virus particles. J. Histochem. Cytochem., 29: 959-968, 1981.
42. Brons, P. P. T., Pennings, A. H. M., Haanen, C., Wessels, H. M. C., and Boezeman, J. B. M. Simultaneous measurement of DNA content and cell-surface immunofluorescence of human bone marrow cells using a single laser flow cytometer. Cytometry, 11: 837-844, 1990.
43. Hulin, N., Conte, P. F., and Pileri, A. Biology of the human myeloma cell population. II. Cytokinetic characteristics. Clin. Lab., 8: 49-55, 1978.
44. Haraldsdottir, V., Haanen, C., Kalsbeek-Batenburg, E., and Olthuis, F. S-phase cells of the lymphoplasmocytic compartment in hyperdiploid multiple myeloma are diploid cells. Cytometry, 21: 203-210, 1995.
45. Sawyer, J. R., Waldron, J. A., Jagannath, S., and Barlogie, B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet. Cytogenet., 83: 41-49, 1995.
46. Tabernero, D., San Miguel, J. F., Garcia-Sanz, R., Najera, L., Garcia-Isidoro, M., Perez-Simon, J. A., Raap, A. K., and Orfao, A. Incidence of chromosome numerical changes in multiple myeloma Fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am. J. Pathol., 149: 153-161, 1996.
47. Zandecki, M., Lai, J. L., and Facon, T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br. J. Haematol., 94: 217-227, 1996.
48. Zandecki, M., Bernardi, F., Genevieve, F., Lai, J. L., Preudhomme, C., Flactif, M., Cosson, A., Bauters, F., and Facon, T. Involvement of peripheral blood cells in multiple myeloma: chromosome changes are the rule within circulating plasma cells but not within B lymphocytes. Leukemia, 11: 1034-1039, 1997.
49. Pilarski, L. M., Szczepek, A. J., Mant, M. J., and Belch, A. R. Cryptic expression of the CD19 epitope detected by mAb Leu12 distinguishes malignant from residual polyclonal B cells in the blood of myeloma patients. Blood, 90: 349a-349a, 1997.
50. Pilarski, L. M., Szczepek, A., MacDonald, H., Mant, M. J., and Belch, A. R. Single cell IgH CDR3 and in situ RT-PCR for IgH CDR3 and Ig light chain unequivocally confirm that circulating CD19+ cells in multiple myeloma are B cells. Blood, 86: 58a, 1995.
51. Crainie, M., Mant, M. J., Belch, A. R., and Pilarski, L. M. Overexpression of the hyaluronan receptor RHAMM characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM isoforms. Blood, 93: 1684-1696, 1999.
52. Kimlinger, T., and Witzig, T. E. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma. Bone Marrow Transplant., 19: 553-556, 1997.
53. Vescio, R. A., Hong, C. H., Cao, J., Kim, A., Schiller, G. J., Lichtenstein, A. K., Berenson, R. J., and Berenson, J. R. The hematopoietic stem cell antigen CD34 is not expressed on the malignant cells in multiple myeloma. Blood, 84: 3283-3290, 1994.